Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants

Science

Volumn 301, Issue 5634, 2003, Pages 805-809

  Santarelli, Luca ^a   Saxe, Michael ^a   Gross, Cornelius ^a   Surget, Alexandre ^b   Battaglia, Fortunato ^c   Dulawa, Stephanie ^a   Weisstaub, Noelia ^a   Lee, James ^a   Duman, Ronald ^d   Arancio, Ottavio ^c   Belzung, Catherine ^b   Hen, René ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITÉ DE TOURS   (France)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN; GENETIC ENGINEERING; RADIOLOGY;

NEUROGENESIS;

NEUROLOGY;

ANTIDEPRESSANT AGENT; DESIPRAMINE; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

BEHAVIORAL RESPONSE; DRUG PRESCRIBING; MENTAL HEALTH;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HIPPOCAMPUS; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; X IRRADIATION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BEHAVIOR, ANIMAL; CELL DIVISION; CONDITIONING (PSYCHOLOGY); DENTATE GYRUS; FEAR; FEEDING BEHAVIOR; FLUOXETINE; GROOMING; HIPPOCAMPUS; LONG-TERM POTENTIATION; MALE; MICE; MICE, KNOCKOUT; NEURONS; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; STRESS; SYNAPTIC TRANSMISSION;

ANIMALIA; HIPPOCAMPUS HIPPOCAMPUS;

EID: 0042528720     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1083328     Document Type: Article

References (42)

1. M. L. Wong, J. Licinio, Nature Rev. Neurosci. 2, 343 (2001).
2. T. V. Gurvits et al., Biol. Psychiatry 40, 1091 (1996).
3. P. J. Shah, K. P. Ebmeier, M. F. Glabus, C. M. Goodwin, Br. J. Psychiatry 172, 527 (1998).
4. Y. I. Sheline, P. W. Wang, M. H. Gado, J. G. Csemansky, M. W. Vannier, Proc. Natl. Acad. Sci. U.S.A. 93, 3908 (1996).
5. B. Czeh et al., Proc. Natl. Acad. Sci. U.S.A. 98, 12796 (2001).
6. B. S. McEwen, Annu. Rev. Neurosci. 22, 105 (1999).
7. R. S. Duman, G. R. Heninger, E. J. Nestler, Arch. Gen. Psychiatry 54, 597 (1997).
8. R. Sapolsky, Stress, the Aging Brain and the Mechanism of Neuron Death (MIT Press, Cambridge, MA, 1992).
9. E. Gould, P. Tanapat, B. S. McEwen, G. Flugge, E. Fuchs, Proc. Natl. Acad. Sci. U.S.A. 95, 3168 (1998).
10. J. E. Malberg, A. J. Eisch, E. J. Nestler, R. S. Duman, J. Neurosci. 20, 9104 (2000).
11. J. M. Garcia-Verdugo, F. Doetsch, H. Wichterle, D. A. Lim, A. Alvarez-Buylla, J. Neurobiol. 36, 234 (1998).
12. E. Gould, C. G. Gross, J. Neurosci. 22, 619 (2002).
13. H. van Praag et al., Nature 415, 1030 (2002).
14. J. F. Cryan, A. Markou, I. Lucki, Trends Pharmacol. Sci. 23, 238 (2002).
15. S. R. Bodnoff, B. Suranyi-Cadotte, D. H. Aitken, R. Quidon, M. J. Meaney, Psychopharmacology 95, 298 (1988).
16. The NSF is a conflict test that elicits competing motivations: the drive to eat and the fear of venturing into the center of a brightly lit arena. Latency to begin eating has been used as an index of anxiety-like behavior because classical anxiolytic drugs decrease it.
17. Fluoxetine is an SSRI. Imipramine is a TCA that blocks the reuptake of both S-HT and NA. Desipramine is a TCA that selectively blocks NA reuptake. Haloperidol is a neuroleptic devoid of antidepressant activity.
18. P. A. Sargent et al., Arch. Gen. Psychiatry 57, 174 (2000).
19. C. Gross et al., Nature 416, 396 (2002).
20. E. Tada, J. M. Parent, D. H. Lowenstein, J. R. Fike, Neuroscience 99, 33 (2000).
21. See materials and methods on Science Online.
22. R. Nagai, S. Tsunoda, Y. Hori, H. Asada, Surg. Neurol. 53, 503 (2000).
23. L. Santarelli et al., data not shown.
24. G. Griebel et al., Proc. Natl. Acad. Sci. U.S.A. 99, 6370 (2002).
25. J. E. LeDoux, P. Cicchetti, A. Xagoraris, L. M. Romanski, J. Neurosci. 10, 1062 (1990).
26. J. M. Gorman, J. Clin. Psychiatry 63, 17 (2002).
27. P. L. Delgado et al., Biol. Psychiatry 46, 212 (1999).
28. M. E. Page, M. J. Detke, A. Dalvi, L. G. Kirby, L. Lucki, Psychopharmacology 147, 162 (1999).
29. S. Ramboz et al., Proc. Natl. Acad. Sci. U.S.A. 95, 14476 (1998).
30. N. McNaughton, Pharmacol. Biochem. Behav. 56, 603 (1997).
31. H. Eichenbaum, Curr. Biol. 9, R482 (1999).
32. J. A. Gray, N. MaNaughton, The Neuropsychology of Anxiety (Oxford Univ. Press, Oxford, ed. 2, 2000).
33. G. Kempermann, Bipolar Disord. 4, 17 (2002).
34. J. Menard, D. Treit, Behav. Pharmacol. 9, 93 (1998).
35. S. E. File, P. J. Kenny, S. Cheeta, Pharmacol. Biochem. Behav. 66, 65 (2000).
36. J. Menard, D. Treit, Brain Res. 888, 163 (2001).
37. R. M. Deacon, D. M. Bannerman, J. N. Rawlins, Behav. Neurosci. 116, 494 (2002).
38. A. Degroot, D. Treit, Brain Res. 949, 60 (2002).
39. D. M. Bannerman et al., Behav. Neurosci. 116, 884 (2002).
40. Y. Shirayama, A. Chen, S. Nakagawa, D. Russell, R. Duman, J. Neurosci. 22, 3251 (2002).
41. G. J. Moore et al., Lancet 356, 1241 (2000).
42. We thank J. Malberg, A. Dhilla, and G. Johnson for their help; W. Dauer, M. Groszer, E. Kandel, P. Rakic, G. Fishbach, F. Gage, A. Kriegstein, and J. Goldman for comments and suggestions; and N. Annenberg for his support. Supported by grants from the National Institute on Drug Abuse (R.H.). National Institute of Mental Health (R.H.), and National Alliance for Research on Schizophrenia and Depression (R.H. and LS.).